Home / Cervical Cancer / Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020

Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020

Published: Oct 2011 | No Of Pages: 28 | Published By: GlobalData

Product Synopsis

GlobalDatas pharmaceuticals report, Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020 provides Cervarix sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Cervical Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Cervarix including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Cervarix including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2007-2020 for Cervarix in the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of contents 3
1.1 List of Tables 4
1.2 List of Figures 4

2 Introduction 5
2.1 Cervical Cancer Vaccines Market 5
2.2 Epidemiology 5
2.3 Etiology 7
2.3.1 HPV Infections 7
2.3.2 Lack of Regular Papanicolaou (pap) Tests 8
2.3.3 Smoking 8
2.3.4 Sexual History 9
2.3.5 Birth Control Pills 9
2.4 GlobalData Report Guidance 9

3 Cervical Cancer Vaccines: Market Characterization 10
3.1 Cervical Cancer Vaccines Market 10
3.2 Drivers and Challenges for the Cervical Cancer Market 10
3.2.1 Drivers for Cervical Cancer Vaccine Market 10
3.2.2 Challenges for Cervical Cancer Vaccines 11

4 Cervarix 12
4.1 Introduction 12
4.2 Mechanism of Action 12
4.3 Clinical Studies 12
4.4 Approval History 13
4.5 Factors Affecting Sales of Cervarix 14
4.5.1 High Efficacy 14
4.5.2 High Cost Effectiveness 14
4.5.3 Large Target Population 14
4.5.4 Limited Competition 14
4.5.5 Low Compliance 14
4.6 Vaccine Evaluation 14
4.6.1 Efficacy 14
4.6.2 Safety 15
4.6.3 Dosing Convenience 15
4.7 Intensity of Competition 15
4.8 Sales forecast 15
4.8.1 Target Population of Cervarix 15
4.8.2 Dosing 16
4.8.3 Market Penetration 16
4.8.4 Annual Cost of Therapy 16
4.8.5 Sales Projections of Cervarix 16

5 Cervical Cancer Vaccine Market: Appendix 25
5.1 Market Definitions 25
5.2 List of Abberiviations 25
5.3 Research Methodology 25
5.3.1 Coverage 26
5.3.2 Secondary Research 26
5.3.3 Forecasting 26
5.3.4 Population Approved to take Vaccine 27
5.3.5 Net Penetration of Vaccine 27
5.3.6 Net Annual Dosing 27
5.3.7 Annual Cost of Therapy 27
5.3.8 Primary Research 27
5.3.9 Expert Panels 28
5.4 Contact Us 28
5.5 Disclaimer 28
5.6 Sources 28

Table 1: Cervical Cancer, Estimated Incidences and Mortality, 2010-2020 6
Table 2: Estimated Prevalence of HPV in 9-26 years women 8
Table 3: Cervarix History 13
Table 4: Cervarix Approval and Expiry 13
Table 5: Cervarix, Cervical Cancer, the US, EU-5 and Japan, Estimated Sales($m), 2007-2020 17
Table 6: Cervarix, Cervical Cancer, the US, Estimated Sales($m), 2009-2020 18
Table 7: Cervarix, Cervical Cancer, the UK, Estimated Sales($m), 2007-2020 19
Table 8: Cervarix, Cervical Cancer, France, Estimated Sales($m), 2007-2020 20
Table 9: Cervarix, Cervical Cancer, Germany, Estimated Sales($m), 2007-2020 21
Table 10: Cervarix, Cervical Cancer, Italy, Estimated Sales($m), 2007-2020 22
Table 11: Cervarix, Cervical Cancer, Spain, Estimated Sales($m), 2007-2020 23
Table 12: Cervarix, Cervical Cancer, Japan, Estimated Sales($m), 2009-2020 24

Figure 1: Estimated Prevalence of HPV in Women Aged between 9-26 Years in the US,EU-5 and Japan, 2010-2020 1
Figure 2: Cervarix, Cervical Cancer, the US, EU-5 and Japan, Estimated Sales($m), 2007-2020 2
Figure 3: Distribution of Incidence and Mortality, Global, Top 26 Diagnosed Cancers,2010 5
Figure 4: Difference Between Percentage Distribution of Incidence and Mortality of Top 19 Cancers, 2008 7
Figure 5: Per Capita Cigarette Consumption, the US, 1976-2006 8
Figure 6: Target Population 15
Figure 7: Cervarix, Cervical Cancer, the US, EU-5 and Japan, Estimated Sales($m), 2007-2020 17
Figure 8:Cervarix, Cervical Cancer, the US, Estimated Sales($m), 2009-2020 18
Figure 9:Cervarix , Cervical Cancer, the UK, Estimated Sales($m), 2007-2020 19
Figure 10:Cervarix, Cervical Cancer, France, Estimated Sales($m), 2007-2020 20
Figure 11:Cervarix, Cervical Cancer, Germany, Estimated Sales($m), 2007-2020 21
Figure 12:Cervarix, Cervical Cancer, Italy, Estimated Sales($m), 2007-2020 22
Figure 13:Cervarix, Cervical Cancer, Spain, Estimated Sales($m), 2007-2020 23
Figure 14: Cervarix, Cervical Cancer, Japan, Estimated Sales($m), 2009-2020 24
Figure 15: GlobalData Methodology 25

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +